Oncotype DX® Colon Cancer Assay - stage II and III colon tumors
Oncotype DX® Colon Cancer Assay is a diagnostic test that has been clinically validated in recurrence risk study of stage II and III colon cancer in 3 prospective studies1-3.The purpose of this assay, which examines the status of several genes on the molecular level in patients with colon cancer, is to provide information on an individual biological status of every tumor. Oncotype DX® Colon Cancer Assay explores specific genes in colon cancer cells to estimate certain probability whether the cells may continue spreading even after cancer tissue removal by surgical resection and thus whether the disease may return. The thus obtained information has proven its independent value compared to currently used parameters for estimating colon cancer recurrence. Information obtained using Oncotype DX® Colon Cancer Assay may be beneficial for planning an optimum therapy in patients with newly diagnosed stage II or III colon cancer disease.
For further information about Oncotype DX® Colon Cancer Assay contact us by phone +420 603 413 160 or by e-mail at email@example.com.
You can also find more information about Genomic Health, Inc. at www.genomichealth.com.
Please visit www.oncotypedx.com for more detailed information about Oncotype DX® in English.
Oncotype DX® Colon Cancer Assay is not currently reimbursed from public health insurance resources. The test can be paid by patients from their own resources. Please do not hesitate to contact us by phone or email (contacts) for more detailed information about the price.
- Gray RG, Quirke P, and Handley K. Validation study of a quantitative multi-gene RT-PCR assay for assessment of recurrence risk in stage II colon cancer patients. J Clin Oncol. 2011; 29: 4611-9.
- Venook AP, Niedzwiecki D, Lopatin M, et al. Validation of a 12-gene colon cancer recurrence score (RS) in patients (pts) with stage II colon cancer (CC) from CALGB 9581. Poster presented at the ASCO Annual Meeting; 2011; Chicago, IL.
- O'Connell MJ, Lee M, Lopatin M, et al. Validation of the 12-gene colon cancer Recurrence Score result in NSABP C-07 as a predictor of recurrence in stage II and II colon cancer patients treated with 5FU/LV (5FU) and 5FU/LV + oxaliplatin (5FU+Ox). Poster presented at the ASCO Annual Meeting; 2012; Chicago, IL.